A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccines

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Human Gene Therapy

• Publication date

  1999-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/10430349950017347PMID 10466632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer vaccines

  2005cited by this paper
• Therapeutic vaccination for cancer.

  2000cited by this paper
• The history of the development of vaccines for the treatment of lymphoma.

  2000cited by this paper
• Uses of granulocyte-macrophage colony-stimulating factor in vaccine development

  2000cited by this paper
• Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

  1999cited by this paper
• The use of gene transfer in cancer immunotherapy.

  1998cited by this paper
• Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.

  1998cited by this paper
• Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic Vaccine

  1998cited by this paper
• CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

  1998cited by this paper
• Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Cancer vaccines

  1998cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

  1997cited by this paper
• Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells.

  1997cited by this paper
• Enhanced immune priming with spatial distribution of paracrine cytokine vaccines.

  1996cited by this paper
• Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.

  1996cited by this paper
• Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.

  1996cited by this paper
• Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials.

  1995cited by this paper
• Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

  1994cited by this paper
• In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

  1994influential reference
• Demonstration of a rational strategy for human prostate cancer gene therapy.

  1994cited by this paper
• Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.

  1994cited by this paper
• Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

  1992cited by this paper
• Differences in antigen presentation to MHC class I-and class II- restricted influenza virus-specific cytolytic T lymphocyte clones

  1986cited by this paper

• A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma

  2024cites this paper
• Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies.

  2022cites this paper
• An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission

  2021influential citation
• Whole tumor cell vaccines engineered to secrete GM‐CSF (GVAX)

  2021cites this paper
• Myelodysplastic syndrome and immunotherapy novel to next in-line treatments

  2021cites this paper
• Whole leukemia cell vaccines: Past progress and future directions.

  2020cites this paper
• The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy.

  2017cites this paper
• Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles.

  2017cites this paper
• An effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model

  2016cites this paper
• Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma

  2016cites this paper
• Immunotherapy in kidney cancer: the past, present, and future

  2016cites this paper
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

  2016cites this paper
• Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.

  2015cites this paper
• Haematological malignancies: at the forefront of immunotherapeutic innovation

  2015cites this paper
• A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model

  2015cites this paper
• A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer

  2014cites this paper
• Immune therapies for malignant mesothelioma

  2014cites this paper
• Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.

  2013cites this paper
• Immunotherapy in Lung Cancer: “B7-Bombers” and Other New Developments

  2013cites this paper
• allogeneic bone marrow chimeras Successful therapy of metastatic cancer using tumor vaccines in mixed

  2013cites this paper
• Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy

  2013cites this paper
• Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

  2013cites this paper
• Developing strategies in the immunotherapy of leukemias.

  2013cites this paper
• Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell–based Vaccine for Refractory Lung Adenocarcinoma

  2013cites this paper
• Modern Molecular and Clinical Approaches to Eradicate HPVMediated Cervical Cancer

  2013cites this paper
• expressed on artificial antigen-presenting cells of tumor necrosis factor receptor family members OX40 and 4-1BB Umbilical cord blood regulatory T-cell expansion and functional effects

  2013cites this paper
• Dendritic Cells and Peptide-Based Vaccine In Multiple Myeloma

  2013cites this paper
• A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma

  2013cites this paper
• transplantation (ASCT) as postremission therapy for acute myeloid cellular immunotherapy in combination with autologous stem cell secreting - Granulocyte-macrophage colony-stimulating factor (GM-CSF)

  2013cites this paper
• Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

  2013cites this paper
• Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape

  2012cites this paper
• Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

  2012cites this paper
• Characterization of chronic myeloid leukemia stem cells

  2011cites this paper
• Evaluation of current cancer immunotherapy: hemato-oncology.

  2011cites this paper
• Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy

  2011cites this paper
• Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas.

  2010cites this paper
• K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

  2010influential citation
• Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.

  2009cites this paper
• Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

  2009cites this paper
• Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

  2009cites this paper
• The biological basis for immunotherapy in patients with chronic myelogenous leukemia.

  2009cites this paper
• Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.

  2009cites this paper
• Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.

  2008cites this paper
• Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.

  2008cites this paper
• Gene therapy for the treatment of cancer: From laboratory to bedside

  2008cites this paper
• Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells

  2008cites this paper
• Immunotherapy for myeloid leukemias: current status and future directions

  2008cites this paper
• Combination of Fasl and GM‐CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma

  2008cites this paper
• Chapter 54 – Cancer-Specific Vaccines

  2008cites this paper
• Immunotherapy for head and neck cancer.

  2008cites this paper
• Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

  2007cites this paper
• General Principles of Tumor Immunotherapy

  2007cites this paper
• A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease

  2007cites this paper
• Immunomodulatory Molecules of the Immune System

  2007cites this paper
• Tumor Vaccines in Leukemia

  2007cites this paper
• GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer

  2007cites this paper
• Award Number: W81XWH-05-1-0279 TITLE: Development of a Novel Therapeutic Paradigm Utilizing a Mammary Gland- Targeted, Bin-1 Knockout Mouse Model

  2007cites this paper
• Award Number: W81XWH-05-1-0279 TITLE: Development of a Novel Therapeutic Paradigm Utilizing a Mammary Gland- Targeted, Bin1-Knockout Mouse Model

  2006cites this paper
• Immune-Modulating Vaccines in Non-small Cell Lung Cancer

  2006cites this paper
• From laboratory to bedside

  2006cites this paper
• Combinatorial cancer immunotherapy.

  2006cites this paper
• GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men

  2006cites this paper
• Vaccine therapies for non-Hodgkin's lymphomas.

  2006cites this paper
• Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma.

  2006cites this paper
• Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer

  2006cites this paper
• Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

  2006cites this paper
• Rapid immune reconstitution and dendritic cell engraftment post-bone marrow transplantation with heterogeneous progenitors and GM-CSF treatment.

  2006influential citation
• Vaccines in cancer: GVAX®, a GM-CSF gene vaccine

  2005cites this paper
• GM-CSF gene-transduced tumor vaccines.

  2005cites this paper
• A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.

  2005cites this paper
• Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility.

  2005cites this paper
• Novel Therapies for Renal Cell Cancer

  2005cites this paper
• Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.

  2005cites this paper
• Immune therapy of chronic myelogenous leukemia.

  2005cites this paper
• Gene-Modified Tumor-Cell Vaccines

  2004cites this paper
• Boosting the immune response: an alternative combination therapy for cancer patients.

  2004cites this paper
• Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

  2004cites this paper
• High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells

  2004influential citation
• Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

  2004cites this paper
• Immunotherapeutic approaches for hematologic malignancies.

  2004cites this paper
• [Active immunotherapy in the treatment of haematological neoplasias].

  2004cites this paper
• Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.

  2004cites this paper
• Immunity to chronic myelogenous leukemia.

  2004cites this paper
• Granulocyte-Macrophage Colony Stimulating Factor: An Adjuvant for Cancer Vaccines

  2004cites this paper
• Cytokines in cancer pathogenesis and cancer therapy

  2004cites this paper
• Part II: Vaccines for haematological malignant disorders.

  2004cites this paper
• Role of Hematopoietic Growth Factors As Adjuncts to the Treatment of Hodgkin’s and Non-Hodgkin’s Lymphomas

  2004cites this paper
• BRIEF COMMUNICATION Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non- Small-Cell Lung Cancer

  2004cites this paper
• Inmunoterapia activa en el tratamiento de neoplasias hematológicas

  2004cites this paper
• Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma.

  2003cites this paper
• Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

  2003cites this paper
• Immunotherapy for Lymphomas

  2003cites this paper
• Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.

  2003cites this paper
• Cytokines and Antitumor Immunity

  2003cites this paper
• Lung cancer vaccines and gene therapy.

  2003cites this paper
• Cell-based immune therapy for metastatic renal cancer

  2003cites this paper
• GM‐CSF‐based cancer vaccines

  2002cites this paper
• The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia

  2002cites this paper
• Vaccine therapies for Non-Hodgkin’s Lymphoma

  2002cites this paper
• Emerging cancer-targeted therapies.

  2002cites this paper